. Newell-price, Cushing's syndrome J Lancet, May, vol.13367, issue.9522, pp.1605-1622, 2006.

R. Clayton, Mortality and morbidity in Cushing's disease over 50 years in Stoke-on-Trent
DOI : 10.1210/jc.2010-1942

O. Dekkers, Multisystem Morbidity and Mortality in Cushing's Syndrome: A Cohort Study, The Journal of Clinical Endocrinology & Metabolism, vol.98, issue.6
DOI : 10.1210/jc.2012-3582

R. Feelders, MANAGEMENT OF ENDOCRINE DISEASE: The burden of Cushing's disease: clinical and health-related quality of life aspects, European Journal of Endocrinology, vol.167, issue.3, pp.311-337, 2012.
DOI : 10.1530/EJE-11-1095

L. Nieman, Medical therapy of Cushing's disease Pituitary, pp.77-82, 2002.

X. Bertagna and . Traitement-de-la-maladie-de-cushing, progrès récents Annales d'Endocrinologie, pp.107-110, 2012.

J. Corcuff, Rapid control of severe neoplastic hypercortisolism with metyrapone and ketoconazole, European Journal of Endocrinology, vol.172, issue.4, pp.473-81
DOI : 10.1530/EJE-14-0913

J. Findling, Screening and diagnosis of Cushing's syndrome ,Endocrinol Metab Clin North Am, pp.385-402, 2005.

J. Lindholm, Incidence and Late Prognosis of Cushing's Syndrome: A Population-Based Study, Journal of Clinical Endocrinology & Metabolism, vol.86, issue.1
DOI : 10.1210/jc.86.1.117

G. Arnaldi, Diagnosis and Complications of Cushing???s Syndrome: A Consensus Statement, The Journal of Clinical Endocrinology & Metabolism, vol.88, issue.12
DOI : 10.1210/jc.2003-030871

U. Turpeinen, Determination of urinary free cortisol by HPLC, Clin Chem, vol.43, issue.8, pp.1386-91, 1997.

J. Findling, NEWER DIAGNOSTIC TECHNIQUES AND PROBLEMS IN CUSHING'S DISEASE, Endocrinology and Metabolism Clinics of North America, vol.28, issue.1, pp.191-210, 1999.
DOI : 10.1016/S0889-8529(05)70063-3

K. Lynnette, The Diagnosis of Cushing's Syndrome: An Endocrine SocietyClinical Practice Guideline 15. Casonato A ,Abnormalities of von Willebrand factor are also part of the prothrombotic state of Cushing's syndrome, Blood Coagul Fibrinolysis, vol.10, issue.3, pp.145-51, 1999.

J. Etxabe, Morbidity and mortality in Cushing's disease: an epidemiological approach, Clinical Endocrinology, vol.97, issue.4
DOI : 10.1016/0002-9343(52)90027-2

M. Yaneva and . Mortality-in, Mortality in Cushing's syndrome: data from 386 patients from a single tertiary referral center, European Journal of Endocrinology, vol.169, issue.5, pp.621-628, 2013.
DOI : 10.1530/EJE-13-0320

J. Lambert, Predictors of Mortality and Long-term Outcomes in Treated Cushing's Disease: A Study of 346 Patients, The Journal of Clinical Endocrinology & Metabolism, vol.98, issue.3, 2013.
DOI : 10.1210/jc.2012-2893

G. Ntali and . Mortality-in, Mortality in Cushing's syndrome: systematic analysis of a large series with prolonged follow-up, European Journal of Endocrinology, vol.169, issue.5, pp.715-738, 2013.
DOI : 10.1530/EJE-13-0569

J. Lindholm, Incidence and Late Prognosis of Cushing's Syndrome: A Population-Based Study, Journal of Clinical Endocrinology & Metabolism, vol.86, issue.1
DOI : 10.1210/jc.86.1.117

I. Akaza, Endothelial Dysfunction Aassociated with Hypercortisolism is Reversible in Cushing???s Syndrome, Endocrine Journal, vol.57, issue.3, pp.245-52, 2009.
DOI : 10.1507/endocrj.K09E-260

N. Sarlis, Cortisolemic Indices Predict Severe Infections in Cushing Syndrome Due to Ectopic Production of Adrenocorticotropin, Journal of Clinical Endocrinology & Metabolism, vol.85, issue.1, pp.42-49, 2000.
DOI : 10.1210/jc.85.1.42

L. Nieman, Successful Treatment of Cushing???s Syndrome with the Glucocorticoid Antagonist RU 486*, The Journal of Clinical Endocrinology & Metabolism, vol.61, issue.3, pp.536-576, 1985.
DOI : 10.1210/jcem-61-3-536

M. Barahona, Persistent Comorbidities in Cushing's Syndrome after Endocrine Cure, Front Horm Res, 2010.

F. Fallo, Effect of surgical treatment on hypertension in Cushing's syndrome, American Journal of Hypertension, vol.9, issue.1, pp.77-80, 1996.
DOI : 10.1016/0895-7061(95)00299-5

A. Colao, Persistence of increased cardiovascular risk in patients with Cushing's disease after five years of successful cure, J Clin Endocrinol Metab, vol.84, issue.8, pp.2664-72, 1999.

M. Bolland, Mortality and morbidity in Cushing???s syndrome in New Zealand, Clinical Endocrinology, vol.84, issue.4, pp.436-478, 2011.
DOI : 10.1111/j.1365-2265.2011.04124.x

E. Resmini and . Persistent, Comorbidities in Cushing's Syndrome after Endocrine Cure Advances in EndocrinologyVolume, Article ID 231432, p.231432, 2014.

I. Ilias, Cushing???s Syndrome Due to Ectopic Corticotropin Secretion: Twenty Years??? Experience at the National Institutes of Health, The Journal of Clinical Endocrinology & Metabolism, vol.90, issue.8, pp.4955-62, 2005.
DOI : 10.1210/jc.2004-2527

G. Abiven, Clinical and Biological Features in the Prognosis of Adrenocortical Cancer: Poor Outcome of Cortisol-Secreting Tumors in a Series of 202 Consecutive Patients, The Journal of Clinical Endocrinology & Metabolism, vol.91, issue.7, pp.2650-2655, 2006.
DOI : 10.1210/jc.2005-2730

L. Nieman, Treatment of Cushing's Syndrome

B. Biller, Treatment of Adrenocorticotropin-Dependent Cushing???s Syndrome: A Consensus Statement, The Journal of Clinical Endocrinology & Metabolism, vol.93, issue.7, 2008.
DOI : 10.1210/jc.2007-2734

C. J. Patil and C. , Late Recurrences of Cushing???s Disease after Initial Successful Transsphenoidal Surgery, The Journal of Clinical Endocrinology & Metabolism, vol.93, issue.2, pp.358-62, 2007.
DOI : 10.1210/jc.2007-2013

J. Estrada and T. Long, Term Outcome of Pituitary Irradiation after Unsuccessful Transsphenoidal Surgery in Cushing's Disease Castinetti F, Gamma knife radiosurgery is a successful adjunctive treatment in Cushing's disease, N Engl J Med Eur J Endocrinol, vol.336156, issue.381, pp.172-177, 1056.

G. Becker, Radiation therapy in the multimodal treatment approach of pituitary adenoma Strahlenther Onkol HAS, Place de l'irradiation intracranniene en conditions stéreotaxique, pp.173-86, 2002.

J. Chow, Bilateral laparoscopic adrenalectomy for corticotrophin???dependent Cushing's syndrome: a review of the Mayo Clinic experience, Clinical Endocrinology, vol.116, issue.2, pp.513-522, 2008.
DOI : 10.1111/j.1464-410X.2004.04586.x

G. Assié, Corticotroph Tumor Progression after Adrenalectomy in Cushing???s Disease: A Reappraisal of Nelson???s Syndrome, The Journal of Clinical Endocrinology & Metabolism, vol.92, issue.1, pp.172-181, 2006.
DOI : 10.1210/jc.2006-1328

R. Pivonello, The Medical Treatment of Cushing???s Disease: Effectiveness of Chronic Treatment with the Dopamine Agonist Cabergoline in Patients Unsuccessfully Treated by Surgery, The Journal of Clinical Endocrinology & Metabolism, vol.94, issue.1, 2008.
DOI : 10.1210/jc.2008-1533

A. Godbout, Cabergoline monotherapy in the long-term treatment of Cushing's disease, European Journal of Endocrinology, vol.163, issue.5, pp.709-725, 2010.
DOI : 10.1530/EJE-10-0382

P. Burman, Limited value of cabergoline in Cushing's disease: a prospective study of a 6-week treatment in 20 patients, European Journal of Endocrinology, vol.174, issue.1, pp.17-24
DOI : 10.1530/EJE-15-0807

C. Annamaria, Month Phase 3 Study of Pasireotide in Cushing's Disease, N Engl J Med, vol.366, pp.914-924, 2012.

R. Pivonello, Pasireotide treatment significantly improves clinical signs and symptoms in patients with Cushing's disease: results from a Phase III study, Clinical Endocrinology, vol.362, issue.Suppl 1, p.2014
DOI : 10.1111/cen.12431

Y. Reznik, Hyperglycemia induced by somatostatin analog pasireotide for the treatment of Cushing's disease Médecine des maladies MétaboliquesVolume 9, 2015.

G. Weckbecker, SOM230: A New Somatostatin Peptidomimetic with Potent Inhibitory Effects on the Growth Hormone/Insulin-Like Growth Factor-I Axis in Rats, Primates, and Dogs, Endocrinology, vol.143, issue.10, pp.4123-4153, 2002.
DOI : 10.1210/en.2002-220219

F. Castinetti, Merits and pitfalls of mifepristone in Cushing's syndrome, European Journal of Endocrinology, vol.160, issue.6, pp.1003-1010, 2009.
DOI : 10.1530/EJE-09-0098

M. Fleseriu and M. , Mifepristone, a Glucocorticoid Receptor Antagonist, Produces Clinical and Metabolic Benefits in Patients with Cushing's Syndrome, The Journal of Clinical Endocrinology & Metabolism, vol.97, issue.6, pp.2039-2088
DOI : 10.1210/jc.2011-3350

F. Castinetti, The use of the glucocorticoid receptor antagonist mifepristone in Cushing??s syndrome, Current Opinion in Endocrinology & Diabetes and Obesity, vol.19, issue.4, pp.295-304
DOI : 10.1097/MED.0b013e32835430bf

E. Daniel, THERAPY OF ENDOCRINE DISEASE: Steroidogenesis enzyme inhibitors in Cushing's syndrome, European Journal of Endocrinology, vol.172, issue.6, pp.263-8014, 2015.
DOI : 10.1530/EJE-14-1014

J. Luton, Treatment of Cushing's disease by O,p'DDD. Survey of 62 cases, Treatment of Cushing's disease by O,p'DDD

C. Baudry, Efficiency and tolerance of mitotane in Cushing's disease in 76 patients from a single center, European Journal of Endocrinology, vol.167, issue.4, pp.473-81, 2012.
DOI : 10.1530/EJE-12-0358

M. Kroiss, Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma, Clinical Endocrinology, vol.67, issue.5, pp.585-91, 2011.
DOI : 10.1111/j.1365-2265.2011.04214.x

V. Chortis, Mitotane Therapy in Adrenocortical Cancer Induces CYP3A4 and Inhibits 5??-Reductase, Explaining the Need for Personalized Glucocorticoid and Androgen Replacement, The Journal of Clinical Endocrinology & Metabolism, vol.98, issue.1, pp.161-71, 2012.
DOI : 10.1210/jc.2012-2851

N. Nader, Mitotane Has an Estrogenic Effect on Sex Hormone-Binding Globulin and Corticosteroid-Binding Globulin in Humans, The Journal of Clinical Endocrinology & Metabolism, vol.91, issue.6, pp.2165-70, 2006.
DOI : 10.1210/jc.2005-2157

K. Alexandraki, Assessment of serum-free cortisol levels in patients with adrenocortical carcinoma treated with mitotane: a pilot study, Clinical Endocrinology, vol.89, issue.3, pp.305-316, 2009.
DOI : 10.1111/j.1365-2265.2009.03631.x

N. Sonino, The use of ketoconazole as an inhibitor of steroid production, N Engl J Med, vol.317, issue.13, pp.812-820, 1987.

N. Sonino, Ketoconazole treatment in Cushing's syndrome: experience in 34 patients, Clinical Endocrinology, vol.34, issue.4, pp.347-52, 1991.
DOI : 10.1016/S0168-8278(86)80495-0

F. Castinetti, Ketoconazole in Cushing's Disease: Is It Worth a Try?, The Journal of Clinical Endocrinology & Metabolism, vol.99, issue.5, 2014.
DOI : 10.1210/jc.2013-3628

G. Stalla, Ketoconazole inhibits corticotropic cell function in vitro ,Endocrinology, 1988.

R. Ogawa, Drug-drug interaction profiles of proton pump inhibitors Clin Pharmacokinet, 2010.

D. Rotstein, Stereoisomers of ketoconazole: preparation and biological activity, Journal of Medicinal Chemistry, vol.35, issue.15, pp.2818-2820, 1992.
DOI : 10.1021/jm00093a015

. Clinicaltrials and . Gov, Treatment for Endogenous Cushing's Syndrome, 2013.

D. Morris, The medical management of Cushing's syndrome Ann N Y Acad Sci, 2002.

V. Preda, Etomidate in the Management of Hypercortisolaemia in Cushing's Syndrome, European Journal of Endocrinology, vol.167, issue.2, pp.137-180, 2012.
DOI : 10.1530/EJE-12-0274

D. Calhoun, Effects of a Novel Aldosterone Synthase Inhibitor for Treatment of Primary Hypertension: Results of a Randomized, Double-Blind, Placebo- and Active-Controlled Phase 2 Trial, Circulation, vol.124, issue.18, pp.1945-55, 2011.
DOI : 10.1161/CIRCULATIONAHA.111.029892

L. Amar, Aldosterone Synthase Inhibition With LCI699: A Proof-of-Concept Study in Patients With Primary Aldosteronism, Hypertension, vol.56, issue.5, pp.831-839, 2010.
DOI : 10.1161/HYPERTENSIONAHA.110.157271

X. Bertagna, LCI699, a Potent 11??-hydroxylase Inhibitor, Normalizes Urinary Cortisol in Patients With Cushing's Disease: Results From a Multicenter, Proof-of-Concept Study, The Journal of Clinical Endocrinology & Metabolism, vol.99, issue.4
DOI : 10.1210/jc.2013-2117

D. Rigel, Pharmacodynamic and Pharmacokinetic Characterization of the Aldosterone Synthase Inhibitor FAD286 in Two Rodent Models of Hyperaldosteronism: Comparison with the 11??-Hydroxylase Inhibitor Metyrapone, Journal of Pharmacology and Experimental Therapeutics, vol.334, issue.1
DOI : 10.1124/jpet.110.167148

E. Daniel and E. Of, Effectiveness of Metyrapone in Treating Cushing's Syndrome: A Retrospective Multicenter Study in 195 Patients, The Journal of Clinical Endocrinology & Metabolism, vol.100, issue.11, pp.4146-54
DOI : 10.1210/jc.2015-2616

J. Verhelst and . Short, Short and long-term responses to metyrapone in the medical management of 91 patients with Cushing's syndrome, Clinical Endocrinology, vol.109, issue.2, pp.169-78, 1991.
DOI : 10.1016/S0009-9260(79)80135-X

J. Brossaud, Cross reactions elicited by serum 17-OH progesterone and 11-desoxycortisol in cortisol assays Clin Chim Acta, pp.72-76, 2009.
DOI : 10.1016/j.cca.2009.05.019

P. J. Monaghan, Comparison of serum cortisol measurement by immunoassay and liquid chromatography-tandem mass spectrometry in patients receiving the 11b-hydroxylase inhibitor metyrapone, Annals of Clinical Biochemistry, pp.48-441, 2011.

L. Owen, Cortisol measurement in patients receiving metyrapone therapy, Annals of Clinical Biochemistry, vol.47, issue.6
DOI : 10.1258/acb.2010.010167

. Hawley, An Up-To-Date Assessment of Routine Assay Performance Clin Chem, 2016.

R. Feelders, Pasireotide Alone or with Cabergoline and Ketoconazole in Cushing's Disease, New England Journal of Medicine, vol.362, issue.19
DOI : 10.1056/NEJMc1000094

R. Pivonello, Cabergoline plus Lanreotide for Ectopic Cushing's Syndrome, New England Journal of Medicine, vol.352, issue.23, pp.2457-2458, 2005.
DOI : 10.1056/NEJM200506093522322

F. Pitoia, Rapid response of hypercortisolism to vandetanib treatment in a patient with advanced medullary thyroid cancer and ectopic Cushing syndrome, Archives of Endocrinology and Metabolism, vol.59, issue.4, p.2015
DOI : 10.1590/2359-3997000000057

P. Kamenický and M. , Mitotane, Metyrapone, and Ketoconazole Combination Therapy as an Alternative to Rescue Adrenalectomy for Severe ACTH-Dependent Cushing's Syndrome, The Journal of Clinical Endocrinology & Metabolism, vol.96, issue.9
DOI : 10.1210/jc.2011-0536

C. Oliver, Commentaire : choix des tests diagnostiques dans l'insuffisance corticotrope, Annales d'Endocrinologie Vol, vol.59, 1998.

B. Kikolina, J. Kiang-tech, and E. Roy, Endocrine Testing Protocols: Hypothalamic Pituitary Adrenal Axis, Inc, 2000.

M. C. Temple, Vers un test à la métopirone ambulatoire avec mesure du11désoxycortisolsalivaire par spectrométrie de masse Annales d'Endocrinologie
DOI : 10.1016/j.ando.2015.07.089

M. Jemal, L. High-throughput-quantitative-bioanalysis-by, . Ms, and . Ms, High-throughput quantitative bioanalysis by LC/MS/MS, Biomedical Chromatography, vol.71, issue.6, pp.422-431, 2000.
DOI : 10.1002/1099-0801(200010)14:6<422::AID-BMC25>3.0.CO;2-I